Display options
Cite
Dubiner HB, Noecker R. Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%. Clin Ophthalmol. 2012;6:525-31doi: 10.2147/OPTH.S30690.
Dubiner, H. B., & Noecker, R. (2012). Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%. Clinical ophthalmology (Auckland, N.Z.), 6525-31. https://doi.org/10.2147/OPTH.S30690
Dubiner, Harvey B, and Noecker, Robert. "Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%." Clinical ophthalmology (Auckland, N.Z.) vol. 6 (2012): 525-31. doi: https://doi.org/10.2147/OPTH.S30690
Dubiner HB, Noecker R. Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%. Clin Ophthalmol. 2012;6:525-31. doi: 10.2147/OPTH.S30690. Epub 2012 Mar 29. PMID: 22536047; PMCID: PMC3334204.
Copy Download .nbib Format: NLM
Share it on

Clin Ophthalmol. 2012;6:525-31. doi: 10.2147/OPTH.S30690. Epub 2012 Mar 29.

Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%.

Clinical ophthalmology (Auckland, N.Z.)

Harvey B Dubiner, Robert Noecker

Affiliations

  1. Clayton Eye Center, Morrow, GA.

PMID: 22536047 PMCID: PMC3334204 DOI: 10.2147/OPTH.S30690

Abstract

BACKGROUND: The purpose of this study was to characterize intraocular pressure (IOP) reduction throughout the day with travoprost ophthalmic solution 0.004% dosed once daily in the evening.

METHODS: The results of seven published, randomized clinical trials including at least one arm in which travoprost 0.004% was dosed once daily in the evening were integrated. Means (and standard deviations) of mean baseline and on-treatment IOP, as well as mean IOP reduction and mean percent IOP reduction at 0800, 1000, and 1600 hours at weeks 2 and 12 were calculated.

RESULTS: From a mean baseline IOP ranging from 25.0 to 27.2 mmHg, mean IOP on treatment ranged from 17.4 to 18.8 mmHg across all visits and time points. Mean IOP reductions from baseline ranged from 7.6 to 8.4 mmHg across visits and time points, representing a mean IOP reduction of 30%. Results of the safety analysis were consistent with the results from the individual studies for travoprost ophthalmic solution 0.004%, with ocular hyperemia being the most common side effect.

CONCLUSION: Travoprost 0.004% dosed once daily in the evening provides sustained IOP reduction throughout the 24-hour dosing interval in subjects with ocular hypertension or open-angle glaucoma. No reduction of IOP-lowering efficacy was observed at the 1600-hour time point which approached the end of the dosing interval.

Keywords: intraocular pressure reduction; travoprost ophthalmic solution 0.004%

References

  1. Am J Ophthalmol. 2011 Sep;152(3):340-344.e2 - PubMed
  2. Ophthalmology. 2002 Jul;109(7):1367-71 - PubMed
  3. Am J Ophthalmol. 2001 Oct;132(4):472-84 - PubMed
  4. Ophthalmology. 2010 Sep;117(9):1700-4 - PubMed
  5. Ophthalmology. 2006 Mar;113(3):425-30 - PubMed
  6. Ophthalmology. 2011 Jan;118(1):47-51 - PubMed
  7. Invest Ophthalmol Vis Sci. 1999 Nov;40(12):2912-7 - PubMed
  8. J Glaucoma. 2008 Apr-May;17(3):217-22 - PubMed
  9. Ophthalmology. 2005 Oct;112(10):1670-5 - PubMed
  10. J Glaucoma. 2007 Jan;16(1):98-103 - PubMed
  11. Am J Ophthalmol. 2007 Dec;144(6):901-907 - PubMed
  12. Arch Ophthalmol. 2002 Oct;120(10):1268-79 - PubMed
  13. Ophthalmology. 2008 Jul;115(7):1123-1129.e3 - PubMed
  14. Ophthalmology. 2011 Sep;118(9):1766-73 - PubMed
  15. Ophthalmology. 2001 Nov;108(11):1943-53 - PubMed
  16. Graefes Arch Clin Exp Ophthalmol. 2005 Jun;243(6):513-8 - PubMed
  17. Am J Ophthalmol. 1998 Oct;126(4):487-97 - PubMed
  18. Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4439-42 - PubMed
  19. Am J Ophthalmol. 2005 Feb;139(2):320-4 - PubMed
  20. J Glaucoma. 2001 Oct;10(5):414-22 - PubMed
  21. Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1586-90 - PubMed
  22. Ophthalmology. 2009 Apr;116(4):717-24 - PubMed
  23. J Glaucoma. 2012 Apr-May;21(4):209-13 - PubMed
  24. J Glaucoma. 2000 Apr;9(2):134-42 - PubMed
  25. Ophthalmology. 2002 May;109(5):998-1008 - PubMed
  26. Arch Ophthalmol. 2010 Mar;128(3):276-87 - PubMed
  27. Am J Ophthalmol. 1998 Oct;126(4):498-505 - PubMed
  28. Ophthalmology. 2004 Sep;111(9):1627-35 - PubMed
  29. Ophthalmology. 2007 Feb;114(2):205-9 - PubMed
  30. Am J Ophthalmol. 2005 Jul;140(1):1-7 - PubMed
  31. Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30 - PubMed
  32. Eur J Ophthalmol. 2012 Jan-Feb;22(1):34-44 - PubMed

Publication Types